Clinical Trial Update: Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating pharmacodynamics, pharmacokinetics, safety and tolerability of VAY736 in idiopathic pulmonary fibrosis was terminated, with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• VAY736

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: TERMINATED | Results posted: 2023-03-10